Marc Ditmarsch

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

Stephen J. Nicholls, Marc Ditmarsch, John J.P. Kastelein et al. · Nature Medicine · 2022 · 148 citations · Full text

Lipid Disorder, High-intensity Statins, Cardiovascular Disease +10

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

Kausik K. Ray, Marc Ditmarsch, David Kallend et al. · European Heart Journal · 2014 · 86 citations · Full text

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

Nick S. Nurmohamed, Marc Ditmarsch, John J.P. Kastelein · Cardiovascular Research · 2021 · 76 citations · Full text

Hyperlipidemia, Pharmacotherapy, Glucose Tolerance +16

Effect of Short-Term Rosuvastatin Treatment on Estimated Glomerular Filtration Rate

Donald G. Vidt, Susan S. Harris, Fergus McTaggart et al. · The American Journal of Cardiology · 2006 · 74 citations

Hemodialysis, Urology, Renal Function +7

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Christie M. Ballantyne, Marc Ditmarsch, John J.P. Kastelein et al. · Journal of clinical lipidology · 2023 · 68 citations · Full text